Urologic Oncology: Seminars and Original Investigations

Title Publication Date Language Citations
Granulocyte-macrophage colony-stimulating factor−transduced allogeneic cancer cellular immunotherapy: The GVAX® vaccine for prostate cancer2006/09/01English98
Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer2011/05/01English96
Urinary biomarkers in bladder cancer: A review of the current landscape and future directions2021/01/01English95
Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin2013/11/01English92
Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer1995/09/01English90
Impact of surgeon and hospital volume on outcomes of radical prostatectomy2010/05/01English90
A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer2018/02/01English88
Application of metabolomics to prostate cancer2011/09/01English87
Natural history of surgically treated high-risk prostate cancer2015/04/01English87
The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level—Can it rule out clinically significant prostate cancer?2014/01/01English85
Pathologic findings at radical prostatectomy: Risk factors for failure and death2007/03/01English84
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy2012/09/01English83
Urine metabolomics for kidney cancer detection and biomarker discovery2011/09/01English83
Continuing trends in pathological stage migration in radical prostatectomy specimens2004/07/01English83
Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis2011/05/01English81
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer2010/07/01English81
Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma2015/08/01English80
Molecular markers in bladder cancer: A critical appraisal2006/07/01English80
The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: A multi-center randomized trial2013/10/01English80
Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer2013/05/01English79
Role of neutrophils in BCG immunotherapy for bladder cancer2008/07/01English78
Active surveillance with selective delayed intervention for favorable risk prostate cancer2006/01/01English78
Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer2010/09/01English77
Prostate-specific membrane antigen-based imaging2013/02/01English77
The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers2010/09/01English77
Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States2011/11/01English76
Long-term results of primary adenocarcinoma of the urinary bladder: A report on 192 patients2006/01/01English76
A prospective clinical trial of green tea for hormone refractory prostate cancer: An evaluation of the complementary/alternative therapy approach2005/03/01English76
Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma2017/08/01English75
A MicroRNA expression profile defining the invasive bladder tumor phenotype2011/11/01English75